KEGG   VARIANT: 238v1
Entry
238v1                      Variant                                 

Name
EML4-ALK fusion
Gene
ALK  ALK receptor tyrosine kinase [KO:K05119]
Organism
hsa_var Human gene variants (Homo sapiens)
Variation
inversion inv(2)(p21p23)
COSF: 473 463 474
Network
nt06210  ERK signaling
nt06214  PI3K signaling
nt06219  JAK-STAT signaling
nt06220  Calcium signaling
nt06266  Non-small cell lung cancer
  Element
N00007  EML4-ALK fusion kinase to RAS-ERK signaling pathway
N00025  EML4-ALK fusion kinase to PLCG-ERK signaling pathway
N00047  EML4-ALK fusion kinase to PI3K signaling pathway
N00105  EML4-ALK fusion kinase to Jak-STAT signaling pathway
N10003  First-generation tyrosine kinase inhibitor to ALK fusion
Drug target
Crizotinib: D09731<JP/US>
Reference
  Authors
Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW
  Title
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
  Journal
Cell Mol Life Sci 73:1209-24 (2016)
DOI:10.1007/s00018-015-2117-6
Reference
  Authors
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H
  Title
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
  Journal
Nature 448:561-6 (2007)
DOI:10.1038/nature05945
LinkDB

KEGG   VARIANT: 238v2
Entry
238v2                      Variant                                 

Name
First generation TKI-resistant ALK1 mutation
Gene
ALK  ALK receptor tyrosine kinase [KO:K05119]
Organism
hsa_var Human gene variants (Homo sapiens)
Variation
mutation I1171T
COSM: 4381100
Variation
mutation C1156Y
COSM: 99136
Variation
mutation F1174L
COSM: 28061
Variation
mutation L1196M
COSM: 99137
Variation
mutation G1269A
COSM: 1169707
Variation
mutation G1202R
COSM: 144250 4422789
Variation
mutation S1206Y
COSM: 144251 4422788
Network
nt06210  ERK signaling
nt06214  PI3K signaling
nt06219  JAK-STAT signaling
nt06220  Calcium signaling
nt06266  Non-small cell lung cancer
  Element
N00007  EML4-ALK fusion kinase to RAS-ERK signaling pathway
N00025  EML4-ALK fusion kinase to PLCG-ERK signaling pathway
N00047  EML4-ALK fusion kinase to PI3K signaling pathway
N00105  EML4-ALK fusion kinase to Jak-STAT signaling pathway
N10004  Second/third-generation tyrosine kinase inhibitor to ALK fusion
Drug target
Alectinib (DG01625): D10450<JP/US>
Brigatinib: D10866<JP/US>
Ceritinib: D10551<JP/US>
Lorlatinib: D11012<JP/US>
Reference
  Authors
Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW
  Title
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
  Journal
Cell Mol Life Sci 73:1209-24 (2016)
DOI:10.1007/s00018-015-2117-6
Reference
  Authors
Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Janne PA
  Title
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
  Journal
Cancer Res 70:10038-43 (2010)
DOI:10.1158/0008-5472.CAN-10-2956
LinkDB

DBGET integrated database retrieval system